MarginsXMarginsX
Home › Markets › Health Care › TECH

Bio-Techne Corp (TECH)

TECH trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$72.79
-0.01% on the day
Market cap
$11.4B
Large cap
Revenue · 2026
$1.2B
-0.4% on 2025
Net income · 2026
$181.9M
15.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/0001104659-26-100322-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerTECH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000842023

Financials · 2026

LineValue
Revenue$1.2B
Net income$181.9M
Operating income$251.9M
Net margin15.0%
Operating margin20.7%
Revenue growth-0.4%
Cash$264.7M
Total assets$2.6B
P/E (computed)62.9×
P/S (computed)9.4×

Warning signs

Cash runway
Cash-flow positive
$350.0M cash at September 30, 2026
Share count, 1 year
+0.8%
2025-10-30 to 2026-11-02 · -0.7% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$437K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$350.0M cash; operating cash flow $84.4M a quarter.Report 2026-09-30
Shares outstanding157,090,727 (2026-11-02); 155,812,701 a year earlier; 158,150,379 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Minneapolis, Minnesota, United StatesPCAOB Form AP 2026-09-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $437K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$299.7M$28.3M$73.1M$350.0M$200.0M$1.2B10-Q/A 2026-11-12
Q4 2026
2026-06-30
$321.2M$54.6M$95.4M$264.7M$200.0M$1.2B10-K 2026-08-24
Q3 2026
2026-03-31
$311.4M$51.0M$86.7M$209.8M$200.0M$1.2B10-Q 2026-05-06
Q2 2026
2025-12-31
$295.9M$38.0M$82.4M$172.9M$260.0M$1.2B10-Q 2026-02-04
Q1 2026
2025-09-30
$286.6M$38.2M$27.6M$145.0M$300.0M$1.2B10-Q/A 2026-11-12
Q4 2025
2025-06-30
$317.0M-$17.7M$98.2M$162.2M$346.0M$1.2B10-K 2026-08-24
Q3 2025
2025-03-31
$316.2M$22.6M$41.1M$140.7M$330.0M$1.2B10-Q 2026-05-06
Q2 2025
2024-12-31
$297.0M$34.9M$84.3M$177.5M$300.0M$1.2B10-Q 2026-02-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+0.0%
1 month+0.4%
3 months+0.9%
Year to date+23.8%
1 year+19.8%
From 52-week high-0.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
RGENRepligen Corporation$162.78-2.99%$10.4B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
EXELExelixis Inc.$67.10-2.75%$16.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier